How Many Women Died Because They Avoided Estrogen?
This is a modeling analysis, not a new trial. The authors derived a formula that takes the excess mortality seen among hysterectomized women aged 50 to 59 who were assigned to placebo in the Women’s Health Initiative randomized controlled trial and applies it to the whole population of comparable women in the United States, factoring in the drop in estrogen use between 2002 and 2011. Over that 10-year span, starting in 2002, they estimate that a minimum of 18 601 and as many as 91 610 postmenopausal women died prematurely because of the avoidance of estrogen therapy.
Dr. Kumar’s Take
The range here is wide, and I want to be honest about that: this is an extrapolation from trial data to a national population, not a body count. But even the low end of the range describes thousands of women in a single decade, and the direction of the finding is not ambiguous. Estrogen therapy in younger postmenopausal women who have had a hysterectomy is associated with a reduction in all-cause mortality, and use in exactly that group has been falling. When a treatment associated with lower mortality goes unused because of a fear generalized from a different population, that is a failure of communication, and it is the kind of failure that costs lives rather than just costing confusion.
What the Research Shows
The starting point is the excess mortality observed among hysterectomized women aged 50 to 59 in the placebo arm of the Women’s Health Initiative randomized controlled trial. The authors built a formula to project that excess onto the full United States population of women in the same age band and hysterectomy status, incorporating the decline in estrogen use observed between 2002 and 2011. The output is a range: at least 18 601 and up to 91 610 premature deaths over the decade. The authors conclude that estrogen therapy in younger postmenopausal women is associated with a decisive reduction in all-cause mortality, that use in this population is low and still falling, and that the associated annual mortality toll among women aged 50 to 59 runs into the thousands.
How This Works (Biological Rationale)
The population studied here is specific and that specificity matters. These are women who have had a hysterectomy, which means estrogen can be given on its own rather than paired with a progestogen to protect the uterine lining. The mortality signal that drives the whole calculation comes from that estrogen-alone setting in women aged 50 to 59, not from combined therapy and not from women who started treatment much later in life. The endpoint is all-cause mortality, which is the broadest and least gameable outcome available: it counts every death regardless of cause.
Practical Takeaways
- If you have had a hysterectomy and you are in your fifties, estrogen therapy in this group is associated with lower all-cause mortality, so avoidance is not automatically the safe choice
- The mortality signal in this analysis comes from estrogen alone in women who have had a hysterectomy, which is a different situation from combined therapy
- Estrogen use in this group is low and has continued to fall since 2002, which is what the authors are calling attention to
- The authors frame informed discussion between these women and their clinicians as a matter of considerable urgency, so raise it at your next visit rather than waiting
- Treat the 18 601 to 91 610 figure as a modeled range, not a precise count, and let the direction rather than the decimal point guide the conversation
- Ask a clinician who can speak to your own hysterectomy status and age band rather than applying a blanket rule
What This Means for Perimenopause and Menopause Care
The core lesson is about who a finding applies to. A result generated in one population, with one treatment regimen, at one age, spread outward into a general fear of hormone therapy, and this analysis is an attempt to put a number on what that spread cost. Whether the true figure sits near the bottom or the top of the range, the authors’ conclusion is that the conversation between women aged 50 to 59 who have had a hysterectomy and their health care providers needs to happen now, individually, rather than being settled in advance by a blanket recommendation.
Related Studies and Research
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality
- Risks and benefits of hormone therapy: has medical dogma now been overturned?
- The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women
- Sleep disturbance associated with the menopause
- Episode 27: Perimenopause, Menopause, and HRT - What Every Woman Should Know
FAQs
Should all women who have had hysterectomies take estrogen?
This analysis does not turn into a universal prescription. It applies to women aged 50 to 59 who have had a hysterectomy, and in that group the authors argue the default should be an informed discussion with your clinician rather than automatic avoidance.
How certain is it that these deaths were really preventable?
That is not known with precision, and the range from 18 601 to 91 610 reflects that. The estimate comes from applying the excess mortality seen in the placebo arm of a randomized trial to national population data, so the uncertainty is real. What the width of the range does not change is the direction of the association.
What can be done to prevent similar tragedies in the future?
Match the finding to the population it came from. State clearly which treatment, which age group, and which surgical history a result applies to, and keep the decision individual rather than issuing a blanket rule that outlives the evidence behind it.
Bottom Line
Applying the excess mortality seen among hysterectomized women aged 50 to 59 in the WHI placebo arm to the United States population, this analysis estimates that between 18 601 and 91 610 women died prematurely over the decade beginning in 2002 because estrogen therapy was avoided. Estrogen use in this group is low and still falling, and the authors treat the conversation between these women and their clinicians as urgent.
